64th ASH Annual Meeting and Exposition: Author Index E

E. Kellems, R.

17 - Erythrocyte Sphingosine 1 Phosphate Is Essential to Combat HIF1α-Dependent Creatine Shuttle, Macrophage Polarization and Fibrosis

E.V., M.

3609 - Bortezomib Maintenance Appears Feasible, Safe and Effective in Newly Diagnosed Multiple Myeloma in a Resource Limited Setting - a Retrospective Analysis from South India

Eakle, K.

3589 - Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States

Eales, T.

2006 - In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmune^TM

Earle, C.

894 - Phase-Specific Costs of Care in Hematological Malignancies in Ontario, Canada

Earley, E. J.

4050 - Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Early, M. L.

806 - Sickle Cell Disease-Specific Blood Pressure Thresholds for Hypertensive Disorders of Pregnancy: A Multinational Study
1073 - "Buprenorphine, It Works So Differently:" Adults with Sickle Cell Disease Describe Their Experiences Transitioning to Buprenorphine for Treatment of Chronic Pain
3716 - Trajectory of Blood Pressure in Pregnant People with Sickle Cell Disease: A Multinational Study

Easdale, S.

4217 - Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Easton, J.

436 - Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children’s Oncology Group Study

Eaton, N.

2430 - Prothrombotic Transformation of the Endothelium Is Markedly Augmented By Cytokine Priming and Inhibited By Tie2 Activation

Eaton, W.

391 - AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model
393 - Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells
1044 - The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease

Eatrides, J.

2923 - Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma
4770 - Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Ebbesen, L. H.

2109 - Acquired Loss of a Sex Chromosome Is a Positive Prognostic Factor for Patients with Multiple Myeloma Undergoing ASCT

Ebbo, M.

23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry
2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry

Ebens, C. L.

114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
2055 - Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants
2085 - Relevance of Monitoring Thymic Function and Recovery in Interpreting Immune Reconstitution Post Hematopoietic Cell Transplantation in Inborn Errors of Immunity
3389 - Radiation Sparing Reduced Intensity Conditioning for Allogeneic Cell Transplantation in Patients with Dyskeratosis Congenita Comparable to Standard of Care: A Phase III Single Institution Trial

Eberhardt, C. S.

4715 - T Cell Receptor Repertoire Profiling Reveals Breadth of Cellular Responses Against Sars-Cov-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients

Ebert, A. D.

3677 - Sickle Cell Disease Patient Plasma Sensitizes iPSC-Derived Sensory Neurons from Sickle Cell Disease Patients

Ebert, B. L.

119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
929 - Canakinumab Effects on Erythropoiesis, Cardiovascular Risk, and Clonal Hematopoiesis: Proteogenomic Analysis of the Cantos Randomized Clinical Trial
1271 - UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Ebinama, U.

2271 - Risk of Pneumonitis with Immune Checkpoint Inhibitors in Hodgkin’s Lymphoma and Other Hematologic Malignancies: A Retrospective Review from Pharmacovigilance

Ebisawa, K.

3920 - Cooperative Inhibitory Effect of IDH1 Mutation and ASXL1 Mutation on Normal Myeloid Differentiation

Ebraheem, M. S.

3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Ebrahim, T.

1013 - Energy Trial in Warm Autoimmune Hemolytic Anemia (wAIHA): Design of a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nipocalimab, an FcRn Blocker
3645 - Mode of Nipocalimab Action and Pharmacology in Cells and Preclinical Models

Echchannaoui, H.

2770 - The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

Eche, I.

4931 - Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Echeandia, N.

4010 - Unexpectedly High Prevalence of iAMP21 in Children with Acute Lymphoblastic Leukemia in Mexico: A Report from the “Mexico in Alliance with St. Jude” (MAS) Collaborative Group

Eckart, K.

2434 - Neutrophil Extracellular Traps (NETs) Thrombogenicity and Endothelial Cell Toxicity Are Ameliorated By Platelet Factor 4 (PF4): Implications to the Treatment of Sepsis

Ecker, V.

4420 - Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression

Eckert, C.

1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010
4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease
4139 - Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Eckert, D.

1864 - Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection

Eckert, R.

1731 - Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients

Eckert, S.

3484 - Impact of Carotid Geometry on Sickle Cell Diseases-Related Cerebral Vasculopthy Development

Eckhardt, C. L.

1070 - Long-Term Follow-up of Dutch Patients with Sickle Cell Disease Diagnosed By Newborn Screening – Effect on the Morbidity and Mortality in the Netherlands

Eckhert, E.

2872 - Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Eckmann, J.

161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
863 - RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination
2798 - CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Eckrich, D.

3511 - Hydroxyurea Use Among Youth with Sickle Cell Anemia across Eight Care Centers within the United States

Eckrich, M.

986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)

Eckstein, V.

2544 - Cell Cycle and Differentiation Arrest in Senescent Population of Human Hematopoietic Stem and Progenitor Cell Compartment

Economides, A. N.

3654 - TMPRSS6 Inhibition with a Monoclonal Antibody Improves Red Blood Cell Health and Reduces Hepatic Iron Loading in Mouse Models of Iron Overload Diseases

Edahiro, R.

2542 - Detailed Analysis of the Impact of Clonal Hematopoiesis on the Risk of Severe COVID-19 Infection

Edelkamp, Jr., P.

4900 - Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections

Edelmann, J.

1791 - (Peri)Centromeric Rearrangements Are Recurrent Recombination Events in Complex-Karyotype Chronic Lymphocytic Leukemia

Edemir, B.

1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Edemir, S.

1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Edenhofer, S.

343 - Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

Edenstrom, A.

2174 - Dynamic Sickling Assay: Using Enzymatically Induced Hypoxia to Assess Real-Time Sickling Scalable from Large Erythrocyte Populations to Individual Cells

Eder, M.

871 - Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Ederhy, S.

4718 - Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Edgar, C.

3773 - Cognitive Impairment Among Patients with Chronic Immune Thrombocytopenia

Edginton, A. N.

3790 - A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors

Edgren, G.

3097 - Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes

Edin, G.

1268 - RNA Deadenylation Subunit CNOT3 Promotes Myeloid Leukemia By Driving Translation of Oncogenic Targets

Edinger, M.

363 - Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4761 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Ediriwickrema, K.

1574 - Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia

Edison, E. S.

2069 - A Model-Informed Precision Busulfan Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation- Real-World Data

Edjlali, M.

3718 - Cervical Artery Lesions in Adults with Sickle Cell Disease : Are They Disease-Related ?

Edmisson, J.

1871 - Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Edmondson, C.

307 - Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation

Edwards, C. V.

3171 - Mapping and Modelling the Molecular Mechanisms That Drive Clonal Plasma Cell-Derived Amyloidogenic Light Chain Induced Cardiotoxicity

Edwards, C. M.

4477 - MGUS and SMM Plasma Cells Exhibit a Senescence-like Phenotype and Accumulation of Transposable Elements That May Contribute to Disease Progression

Edwards, D.

1574 - Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia

Edwards, J. G.

3525 - Improving Rates of Annual Transcranial Doppler Screening in Children with Sickle Cell Disease: A Quality Improvement Project
- Socioeconomic Disparities and Risk of Stroke As Assessed By Transcranial Doppler: A Displace Study Secondary Analysis

Edwards, T. L.

2415 - Identification and Characterization of a Retrospective Cohort of Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Patients in the US

Edwards, W.

4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Eertink, J. J.

319 - External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Efebera, Y. A.

4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
- The First Relapse in Multiple Myeloma – How to Pick the Next Best Thing
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Efficace, F.

535 - 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
2306 - Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study

Efremov, D. G.

635 - Rapid Generation of Murine CLL/Richter Syndrome Models By Multiplexed CRISPR/Cas9 Editing of Common CLL Driver Genes
3119 - Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Efremova, M.

307 - Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation

Efstathopoulou, M.

1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Efstathopoulou, M.

966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Eftychiadis, E.

3667 - Real-World Data on the Use of Luspatercept in Greek Patients with Transfusion Dependent Thalassemia

Efuni, S.

3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia

Egan, D.

757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Egan, D.

1634 - Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Egan, P. C.

3545 - Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)

Egan-Sherry, D.

3795 - Utility of Von Willebrand Testing during Acute Bleeding Episodes

Egbujo, O.

2195 - Barriers and Facilitators to Community Acceptability of Integrating Point-of-Care Testing to Screen for Sickle Cell Disease in Children in Primary Healthcare Settings in Rural Northern Ghana

Egeler, E. L.

4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Egerer, G.

736 - High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients – a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Egesten, A.

5 - C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis

Eggenschwiler, A.

936 - MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells

Egger-Heidrich, K.

4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Eghtedar, A.

1444 - Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
4639 - A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC‑Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Egle, A.

1302 - TET2 Loss Conspires with MYC to Foster Lymphomagenesis
4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Egnell Gustafsson, C.

2688 - High-Dose Methotrexate-Related Toxicity in Children with Acute Lymphoblastic Leukemia

Egorova, A.

475 - Donor-Derived Amphiregulin Drives CD4⁺ T Cell Expansion and Promotes Tissue Pathology after Experimental Allogeneic BMT
480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39

Eguchi, K.

1460 - Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Eguizábal, C.

1997 - A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)

Egyed, M.

337 - Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Naïve Patients Treated with Momelotinib or Ruxolitinib
627 - Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor
1733 - Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib
4345 - Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)
4348 - Momelotinib (MMB) Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

Ehinger, M.

614 - Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Ehl, S.

1102 - Circulating B-Cell Precursor Cells As Potential Diagnostic and Therapeutic Biomarker in Patients with WHIM Syndrome

Ehlers, L. H.

893 - Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia without Del17p/TP53-Mutation Compared to Chlorambucil Plus Obinutuzumab

Ehli, E.

1719 - Fine-Mapping of SMAD6 Sequence Data Identifies Additional Putative Risk Loci for Langerhans Cell Histiocytosis

Ehlinger, Z.

4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Ehmann, W. C.

3378 - Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Ehninger, A.

979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Ehninger, G.

217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Ehninger, G.

979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Ehnot, J.

3896 - Clonal Diversity As an Alternative Measure for Hematopoietic Reserve in Bone Marrow Failure

Ehrhardt, M. J.

902 - Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort
2920 - Survival of Patients with Extranodal NK-Cell Lymphoma in the United States

Ehrlich, L. A.

- Panel Discussion

Ehrlich, V.

2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Ehrmann, A. S.

1784 - NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted

Eich, H.

317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group

Eichert, N.

4363 - Quantitative MRI Detects Multi-Organ Impairment in Patients with Chronic Myeloid Neoplasms

Eichhorst, B.

343 - Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
3116 - Long-Term Host Immune Changes Following Treatment with Venetoclax Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia
4436 - Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Eichler, E. E.

4809 - Long-Read Sequencing Resolves Complex Structural Variants and Identifies Missing Disease-Causing Variants in Unsolved Cases of Hemophilia

Eichler, H.

1142 - Blood-Induced Inflammation in Hemophilia

Eichmüller, S.

245 - Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Eickhardt-Dalbøge, C. S. S.

743 - Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial
3029 - Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
3043 - Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Eide, C. A.

427 - Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy
1336 - Elvn-001, a Next Generation ATP-Competitive ABL1 Tyrosine Kinase Inhibitor for the Treatment of Chronic Myeloid Leukemia

Eidenschink Brodersen, L.

1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
2168 - A Novel Multi-Analytic Clinical Diagnostic Assay to Detect HLA Loss of Heterozygosity in Post-Hematopoietic Cell Transplant Relapse Patients

Eifert, T.

203 - Pre-Clinical Investigation of a Novel Small Molecule Inhibitor Targeting YBX1 in AML
298 - Functional Role of Histone Variant macroH2A1 (H2AFY) in Acute Myeloid Leukemia (AML)
3903 - Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia

Eikema, D. J.

266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
2130 - Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021
4682 - Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic – a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT
4759 - Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis

Eikema, D. J.

2569 - Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)

Eiken, A. P.

3999 - A Novel Spirocyclic Dimer (SpiD3) Resensitizes CLL Cells to Venetoclax

Eikenboom, J. C.

591 - Colorectal Cancer Screening in Patients with Inherited Bleeding Disorders: High Cancer Detection Rate in Hemophilia Patients

Einarsson Long, T.

4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Einarsson Long, T.

103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study

Einolf, H. J.

3014 - Population Pharmacokinetics in Hepatic and Renal Impairment and PBPK Drug-Drug Interaction Simulations of Asciminib, a Novel Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia in Chronic Phase

Einsele, H.

116 - Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
477 - Endothelial Cells Activate Alloreactive CD4⁺ T Cells to Initiate Acute Graft-Versus-Host Disease
1085 - Exogenous M-CSF Protects from Lethal a. Fumigatus pulmonary Infection By Tissue-Resident Alveolar Macrophages Early after Hematopoietic Cell Transplantation
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling
1883 - Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials
1945 - Harnessing the Expression of TNFR2 on Tregs to Prevent Agvhd
2023 - DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
3138 - Spatial Transcriptomics Reveals a Multi Cellular Ecosystem in Extramedullary Multiple Myeloma
3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3242 - MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
4473 - The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma
4502 - Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
4761 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Eiring, A. M.

1278 - Regulation of Oxidative Energy Metabolism By G0S2 in FLT3⁺ AML
1465 - 19S Proteasome Subunits As Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)

Eiring, P.

1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients

Eischen, C. M.

4801 - Identification of a Novel Nucleoside Prodrug with Preferential Activity in Lymphoma and Leukemia Subtypes

Eisele, J.

773 - Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Eisen, S.

1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Eisenberg, M.

4397 - Impact of the Updated IPSS-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in 10,283 Real World Samples

Eisenkolb, G.

4590 - IFN-Gamma Is Crucial for the Counterbalance of T Cell-Mediated Injury to the Intestinal Stem Cell Compartment By Regulatory T Cells in Mice and Humans

Eisenman, R.

1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML

Eisenstaedt, R. S.

3698 - Comparison of Strokes in Adult Hospitalized Patients with Sickle Cell Disease and Patients without Sickle Cell Disease: A Nationwide Analysis

Eisermann, M.

693 - SLN140 a Small Interfering RNA Targeting Protein S Improves Hemostasis Potency in Hemophilia

Eisfeld, A. K.

Eisfelder, B.

437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
4795 - Targeting Apoptosis with Novel BH3 Mimetics in T-Lineage Acute Lymphoblastic Leukemia

Eisman, S. E.

330 - Jak2^V617F Reversible Activation Shows an Essential Requirement for Jak2^V617F in Myeloproliferative Neoplasms (MPNs)

Eismann, T.

3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients

Eiva, M. A.

3301 - G-CSF Mobilized Apheresis As an Alternative Source of CAR T-Cells

Eiza, N.

3164 - The Involvement of LAG3+ Plasma Cells in the Development of Multiple Myeloma

Ejerblad, E.

3097 - Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes

Ek, S.

745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21^R110
4170 - Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Ekberg, S.

105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study

Ekbom, A.

522 - Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)

Eke, A.

806 - Sickle Cell Disease-Specific Blood Pressure Thresholds for Hypertensive Disorders of Pregnancy: A Multinational Study
3716 - Trajectory of Blood Pressure in Pregnant People with Sickle Cell Disease: A Multinational Study

Ekels, A.

796 - Fatigue, Neuropathy, Psychological Distress and Their Association with Health-Related Quality of Life in Survivors of Diffuse Large B-Cell Lymphoma: A Prospective Cohort Study and Comparison with a Normative Population

Eken, J. A.

631 - Autonomous BCR Signaling and Genetic Aberrations in CLL-Phenotype Monoclonal B Lymphocytosis in Siblings of CLL Patients
2869 - Antigen-Independent, Autonomous B-Cell Receptor Signaling in Diffuse Large B-Cell Lymphoma

Ekiz, A.

3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling

Ekstroem Smedby, K.

1572 - Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
4236 - Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Ekstrom, C.

1332 - Targeting N-Myristoylation for Adult Acute Myeloid Leukemia Therapy

EL Andaloussi, S.

1944 - The Role of N-Acetylcysteine Amide (NACA) As Prophylactic Treatment for Acute Graft-Versus-Host Disease

El Ashkar, S.

2637 - Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

El Ayachi, I.

15 - PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis

El Boghdadly, Z.

4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

El Chaer, F.

240 - Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

El Daker, S.

1551 - High-Resolution Single Cell T-Cell Phenotyping of B-Cell Lineage Lymphomas Reveals Unique Immune Signatures and Potential Targetable Vulnerabilities

El Fakih, R.

4740 - Utility and Validity of Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population

El Hage Chehade, N.

1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study

El Hussein, S.

3492 - Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

El Jurdi, N. H.

114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
4708 - Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
4731 - Quality of Life in Patients Undergoing Double Umbilical Cord Blood Vs. Haploidentical Marrow Transplantation: A QOL Analysis Report of BMT CTN 1101
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

El Naqa, I.

4903 - Associations between Patient-Reported Outcomes and 90-Day Response to Chimeric Antigen Receptor T-Cell Therapy: A Bayesian Network Analysis

El Nemer, W.

2558 - A Functional in Vitro 3D Model of Human Hematopoietic Niches

El Rassi, F.

677 - Interim Analysis of a Phase 2 Trial to Assess the Efficacy and Safety of Crizanlizumab in Sickle Cell Disease Patients with Priapism (SPARTAN)
3717 - COVID-19 Outcomes at a Comprehensive Sickle Cell Center: A Two-Year Report

El Riachy, N.

905 - Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

El Yamani, A.

3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study

El Zarif, T.

2432 - Monogenic and Polygenic Contributions to Venous Thromboembolism (VTE) and Splanchnic Thrombosis in Patients (pts) with Pancreatic Cancer (PC)

El-am, E.

2432 - Monogenic and Polygenic Contributions to Venous Thromboembolism (VTE) and Splanchnic Thrombosis in Patients (pts) with Pancreatic Cancer (PC)

El-Ashwah, S.

1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

El-Dana, F.

1315 - Activin-like Kinase 2 (ALK2/ACVR1) Is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia

El-Galaly, T. C.

- Individualized Outcome Prediction Based on Observational Data.

El-Galaly, T. C. C.

76 - Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial
448 - Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1569 - Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study
2984 - Outcome after 3^rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study
3032 - Statin Use and the Risk of Myeloproliferative Neoplasms in a Population Based Cohort
4236 - Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival
4349 - Metformin Use and the Risk of Myeloproliferative Neoplasms in a Danish Population Based Cohort

El-Jawahri, A.

1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
2292 - Longitudinal Patient-Reported Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
3631 - Discordance between Patient Goals and Treatment in Older AML Patients
3633 - Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation
4937 - Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

El-Kalay, M.

666 - A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

El-Khoury, H.

244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

El-Mallawany, N. K.

703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma
2920 - Survival of Patients with Extranodal NK-Cell Lymphoma in the United States

El-Sharkawi, D.

1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
4217 - Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

El-Sharkawi, D.

3528 - Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Elantably, D.

600 - Racial Disparities in Mortality Trends from Acute Myeloid Leukemia: A Population-Based Study in the United States between 2000 and 2019
1006 - Autoimmune Hemolytic Anemia and Increased Stroke Risk in the United States: A Population-Based Study
1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020

Elavalakanar, P.

141 - Bleeding Risk in Atrial Fibrillation and Thrombocytopenia: A Propensity Matched Cohort Study
1198 - Antiplatelet Medications and Intracranial Hemorrhage in Patients with Primary Brain Tumors
2184 - Survey of U.S. Healthcare Providers to Assess Attitudes and Practices Regarding Thromboprophylaxis of Hospitalized Adult Patients
2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
4935 - Clonal Myeloid Disorders Following CAR T-Cell Therapy

Elbert, M.

1309 - Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Elcheikh, J.

2136 - Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party

Eldar, O.

2499 - Efficacy and Safety of Rivaroxaban Versus Apixaban in Patients with Venous Thromboembolism: A Systematic Review and Meta-Analysis of Observational Studies

Eldem, I.

2455 - Tissue Factor Pathway Inhibitor Gamma Deletion Corrects the Bleeding Phenotype in Hemophilia Mice

Elder, E.

3047 - Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Elder, J.

2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction

Elder, P.

4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme

Eldering, E.

345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
3111 - Dysfunction of T Cells from Chronic Lymphocytic Leukemia (CLL) Patients Is Linked to Disturbed Lipid and Fatty Acid Homeostasis

Eldfors, S.

46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
430 - Monosomy 7 and Del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia

Eldjerou, L. K.

4033 - Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Eldridge, P. W.

1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Elebyary, O.

4699 - A Primed Neutrophil Subset Predicts the Risk of Bloodstream Infections in Allogenic Bone Marrow Transplant Patients: A Prospective Study

Elemary, M.

3411 - Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease

Elemento, O.

67 - The Single-Cell Pathology Landscape of Diffuse Large B Cell Lymphoma
73 - Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma
205 - Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy
704 - The FOXO1^TAD-p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
1348 - PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
4108 - Quantitative Cytogenetic Analysis with karyoParser Allows for More Precise Identification of Disease Biology, Clonal Evolution, and Etiology of Relapse in Acute Myeloid Leukemia

Elena, C.

623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Elena, C.

1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Elenga, N.

183 - Hydroxyurea Is Associated with Later Onset of Occurrence of Acute Splenic Sequestration Episodes in Sickle Cell Disease: Lessons from the European Sickle Cell Disease Cohort – Hydroxyurea (ESCORT-HU) Study
1069 - Long-Term Efficacy and Safety of L-Glutamine in Preventing Sickle Cell Disease-Related Acute Complications and Hemolysis in Pediatric and Adult Patients: A Real-World Observational Study

Elenitoba-Johnson, K. S.

4181 - The NPM1-TYK2 Chimeric Fusion Promotes Activation of STAT Family Signaling, Skewing Towards Tfh Functional Subset Differentiation and Mature T-Cell Lymphomagenesis
4194 - The Role of ARID1a in T Cell Differentiation & Lymphomagenesis

Elessa, D.

4514 - Prognosis of Hyperviscosity Syndrome in Newly Diagnosed Multiple Myeloma in Modern-Era Therapy: A Real-Life Monocentric Study

Eleutherakis Papaiakovou, E.

647 - Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis
1861 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy
1863 - Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center
1920 - A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
3181 - Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes
3234 - Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
3256 - Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

Elf, S.

- Blood Drop: SCHOLAR

Elf, S.

451 - Type 2 but Not Type 1 Calreticulin Mutants Exhibit Loss of Chaperone Function Due to C-Terminal Structural Interference, and Bind to Wild Type Calreticulin in a Dominant Negative Manner
- SCHOLAR

ElGamal, D.

1565 - Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma
3999 - A Novel Spirocyclic Dimer (SpiD3) Resensitizes CLL Cells to Venetoclax

Elgamal, O. A.

1440 - Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
1451 - A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model
4798 - Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Elgamal, S.

2641 - Elucidating the Mechanism of Action (MOA) of Navtemadlin, an MDM2 Inhibitor, and Its Synergy with Gilteritinib in Myeloid Malignancies

Elgammal, Y.

511 - De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts

Elgarten, C. W.

4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

Elgeioushi, N.

4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Elhaddad, A. M.

1668 - Pediatrics Non-Hodgkin’s Lymphoma Survivors: Should We Worry about Quality of Life and Late Therapy Effects?
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Elhag, S.

1565 - Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma

Elhasid, R.

788 - Prediction of Initial Risk Group, B/T Subtype, and ETV6-RUNX1 Translocation in Pediatric Acute Lymphoblastic Leukemia By Deep Convolutional Neural Network Analysis of Giemsa-Stained Whole Slide Images
1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Elhassan, T.

4740 - Utility and Validity of Hematopoietic Cell Transplantation–Comorbidity Index (HCT-CI) in Predicting Overall Survival and Non-Relapse Mortality in Adolescent and Young Adult Population
4753 - Long Term Survival Analysis and Impact of Risk Factors Based Survival Model in Two Hundred Patients with Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant

Elia-Pacitti, J.

3581 - External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Elias, A.

1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin

Elias, H. K.

1215 - Functional and Molecular Heterogeneity of Aging Hematopoietic Stem Cells
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Elias, S.

4767 - Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia

Elias, S. G.

792 - Prediction of Poor Outcome after Tisagenlecleucel in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Using Artificial Intelligence Analysis of Pre-Infusion PET/CT

Elie, J.

3696 - Sputum IL-6 Level Is a Potential Predictor and Severity Marker of Acute Chest Syndrome in Sickle Cell Disease

Elisa, M.

4041 - Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

Eliseev, R. A.

2046 - Mitochondrial Transfer to Host Cells from Ex Vivo Expanded Donor Hematopoietic Stem Cells

Elitzur, S.

49 - Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol
4007 - Familial Predisposition to B-Cell Precursor Acute Lymphoblastic Leukemia Mediated By PAX5 Germline Variants

Elitzur, S.

520 - Thrombin Generation Is Differentially Affected By Anticoagulants in Patients with Acute Lymphoblastic Leukemia – an Ex-Vivo Study

Elkin, R.

4489 - Geometric Network Analysis Defines Poor-Prognosis Subtypes in Multiple Myeloma

Elkind, R.

268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
3541 - Trends in Collection and Utilization of Autologous Hematopoietic Stem Cells (APBHC) Intended for Transplant in Patients with Multiple Myeloma

Elko, T. A.

881 - Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Elkus, H.

499 - Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: Prospective Data from the ITP Consortium of North America (ICON) Quality Improvement Initiative

Ellegast, J. M.

2603 - Mechanisms of the CBFA2T3-GLIS2 Fusion in AML Maintenance

Ellervik, C.

743 - Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial
1717 - Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke
3029 - Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera
3043 - Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms
4322 - Interferon-alpha2 Favorably Impacts Deregulated Atherosclerosis Genes in Polycythemia Vera and Related Neoplasms

Elli, E. M.

2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3625 - Health-Related Quality of Life of Patients with Philadelphia-Negative Myeloproliferative Neoplasms Compared with the General Population: A Preliminary Report from the Gimema Prophecy Study
4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4365 - Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis Is a Predictor of Venous Thrombosis and Poor Outcome in Patients with Prefibrotic Primary Myelofibrosis
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study

Ellin, F.

614 - Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Elliot, B.

4206 - Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R²) Vs R² Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
4251 - Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Elliot, D. E.

4609 - Modulating Donor T Cell Graft-Versus-Host and Graft-Versus-Tumor Reactivity By Stat6

Elliot, E.

377 - Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Elliot, J.

3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Elliott, B.

1663 - Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)
2978 - Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis
4271 - Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Elliott, J. B.

1938 - Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
4203 - Phase II Study of Ibrutinib in Combination with Ixazomib in Patients with Waldenström Macroglobulinemia (WM)

Elliott, M. R.

1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Elliott, M. A.

1233 - Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
2334 - Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Elliott, N.

698 - Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Ellis, A.

1484 - Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML

Ellis, L. R.

4841 - Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique
- How the Personal Characteristics of Grit and Resilience Relate to Physician Well
- Writing a Good CV, Portfolio, and Biosketch
- Breakout Session 4

Ellis, M. H.

3726 - The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Ellis, P.

1463 - Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Ellison, A.

2378 - Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes

Ellison, M.

1102 - Circulating B-Cell Precursor Cells As Potential Diagnostic and Therapeutic Biomarker in Patients with WHIM Syndrome
3739 - Investigating Biomarkers for Primary Immunodeficiency Disorders in Patients with Autoimmune Cytopenia

Ellison, S.

782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA

Ellonen, P.

2418 - Somatic Mutations in T Cells in Patients with Hematological Diseases
3734 - Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Elluru, S. R.

3330 - Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Elmacken, M.

- Diffuse Large B-Cell Lymphoma Second Line Indication - Lisocabtagene maraleucel
- Panel Discussion

Elmariah, H.

365 - Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
538 - Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
4633 - Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Elmariah, H.

779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Elmariah, S.

911 - Clinical Experience with Afamelanotide for the Protoporphyrias in the United States

Elmeliegy, M.

3192 - Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma
4509 - A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Elmuti, L.

1081 - Impact of Viral Infections in Sickle Cell Disease

Elnabarawy, N.

1668 - Pediatrics Non-Hodgkin’s Lymphoma Survivors: Should We Worry about Quality of Life and Late Therapy Effects?

Elnafie, T.

3528 - Does R-IPI Remain Predictive of Relapse Risk for Patients with DLBCL Achieving a Complete Remission with Frontline Therapy: Landmark Analysis of Two Large Prospective Clinical Trials

Eloranta, S.

448 - Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway
4236 - Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Elosua-Bayes, M.

3741 - A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation

Elpek, K.

3457 - CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

Elron, E.

1129 - When Less Is More: Intravenous Immune Globulin for the Treatment of New-Onset Pediatric Immune Thrombocytopenia

Elsawa, S. F.

4193 - Gli3 Is Required for M2 Macrophage Polarization and M2-Mediated Waldenström Macroglobulinemia Growth and Survival
- Laboratory and Translational Hematology

Elsawy, M.

2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Elsayed, A.

531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis

Elsayed, A. H.

432 - Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10

Elsayed, Y.

2637 - Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Elsayed, Y. A.

1342 - Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Elshenawy, M.

4753 - Long Term Survival Analysis and Impact of Risk Factors Based Survival Model in Two Hundred Patients with Primary Refractory Hodgkin Lymphoma Who Underwent High Dose Chemotherapy and Autologous Stem Cell Transplant

Elsherif, L.

1062 - Evaluating Equations for Estimated Glomerular Filtration Rate (eGFR) in Patients with Sickle Cell Disease (SCD)

ElSouda, D.

3627 - Streamline – Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Elstrom, R.

2000 - Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies

Eltaher, B.

4542 - Acute Venous and Arterial Thromboembolic Events in Patients with Monoclonal Gammopathy of Undetermined Significance: A Nation Wide Analysis

Elvarsdottir, E. M.

3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations

Emadi, A.

3964 - Targeting Serine Biosynthesis in Combination with the Modulation of Glutamine Metabolism Enhances Cellular Cytotoxicity in Acute Myeloid Leukemia
3968 - Comprehensive Plasma Amino Acid Analysis Following Administration of Short- and Long-Acting Erwinia Asparaginase (Crisantaspase) Demonstrated Significant Increase in Plasma Serine and Glycine Levels
4075 - Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Emanueli Cippitelli, E.

995 - Domiciliary Nursing Management for Patients Affected By Multiple Myeloma during Covid-19 Pandemia in the Viterbo Home Care Unit: Data Analysis from March 2020 to March 2022

Emberesh, S.

511 - De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts

Emechebe, N.

2307 - Real-World Treatment Patterns and Outcomes of Daratumumab Retreatment in Multiple Myeloma in the United States

Emeribe, U.

1815 - Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features

Emig, M.

168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Emile, J. F.

449 - Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa

Emiliani, C.

1469 - Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia

Emmanuel-Alejandro, E.

3313 - Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Emmel, G.

525 - Stromal STAT5-Mediated Trophic Activity Regulates Hematopoietic Multipotent Progenitor Niche Factors

Emmer, B.

694 - Identification of Critical Proteins Required for Efficient Von Willebrand Factor Secretion Using CRISPR Knockout Screening

Emmerich, C.

1350 - Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Emmert, A.

880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Emond, B.

797 - Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib
4934 - Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation

Emond, P.

1964 - IFN-γ Primed Wharton’s Jelly Mesenchymal Stromal Cells Inhibit T Cell Proliferation By Synergistic IDO and Mitochondrial Transfer Mechanisms

Empson, V.

4345 - Efficacy and Safety of Long-Term Ropeginterferon Alfa-2b Treatment in Patients with Low-Risk and High-Risk Polycythemia Vera (PV)

Enard, W.

2606 - Synergistic Antileukemic Effect of Mek and Lsd1 Inhibitors Correlates with Decreased Phospho-Serine 315 of TP53

Enard, W.

2811 - Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Enblad, G.

315 - Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy
1572 - Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Encinas, C.

162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease

Encinas, C.

1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Encinas, C.

3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Encinas, E.

2627 - Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma

Encinas Mayoral, J.

4471 - CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Enciso, M. E.

4029 - Improvements in AML Treatment Outcomes By Twinning at the Instituto De Prevision Social Hospital in Paraguay

Endell, J.

3971 - The Novel Bispecific Innate Cell Engager (ICE^®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

Enderti, A.

4313 - Haploinsufficiency of Calreticulin Causes Dysregulation of Hematopoiesis and Results in a Myeloproliferative Phenotype in an in-Vivo Mouse Model

Endres, M.

1224 - Associations of Clonal Hematopoiesis with Recurrent Vascular Events and Death in Patients with Incident Ischemic Stroke

Endres, S.

1359 - Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Ener, E.

1271 - UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability

Enevold, C.

1680 - Interferon-alpha2 Treatment Reduces Circulating Neutrophil Extracellular Trap Levels in Myeloproliferative Neoplasms

Engdahl, C.

2530 - Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells from CD123 Targeted Immunotherapy

Engel, B.

1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Engel, B.

4473 - The T-Cell Metabolic Phenotype Is Dependent on Risk Status and Degree of PC Bone Marrow Infiltration in Multiple Myeloma

Engel, E.

3820 - Use of a Calibrated, Drug-Specific DTT Assay to Improve Bivalirudin Monitoring in Pediatric Extracorporeal Membrane Oxygenation (ECMO)

Engel, E.

390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)

Engel, J. D.

3642 - Identification of Novel Regulators of Erythropoiesis Using Whole-Genome CRISPR-Cas9 Screening

Engel, K. L.

2634 - Intracellular Calcium Localization Mediates the Activity of Venetoclax in Targeting Acute Myeloid Leukemia Stem Cells

Engel, P.

4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Engelberts, P. J.

1366 - Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30⁺ Hematologic Malignancies

Engelhardt, B.

4548 - Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Engelhardt, B. G.

987 - Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia
2712 - Insulin Secretion and β-Cell Function Are Preserved in Patients with Treated Hematological Malignancies
3390 - Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide

Engelhardt, M.

116 - Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
4285 - Reduced-Intensity Conditioning Prior Autologous Stem Cell Transplantion in Elderly DLBCL Patients

Engels, B.

983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Engert, A.

317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

England, J. T.

4370 - Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Engleitner, T.

4420 - Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression

Engler, A.

2405 - A Specialized Population of Monocyte-Derived Tracheal Macrophages Promote Airway Epithelial Regeneration

Englisch, C.

521 - Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer

English, M.

1245 - Novel Disease-Causing Mutations in UBA1 Reveal Disease Mechanisms in Bone Marrow Failure and Inflammation

Engstler, G.

49 - Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol
3987 - Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results from the ITCC-059 Phase IA and Phase II Trial
4047 - Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results from the ITCC-059 Phase 1B Trial

Enjeti, A. K.

1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Enjyoji, K.

401 - Coagulation Factor XII Is Activated Via Noncanonical Binding to Platelet Integrin αIIbβ3
2430 - Prothrombotic Transformation of the Endothelium Is Markedly Augmented By Cytokine Priming and Inhibited By Tie2 Activation

Ennajdaoui, H.

3457 - CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

Ennishi, D.

1427 - Gilteritinib Maintenance Therapy Post-Allogenic Stem-Cell Transplantation Improves the Prognosis of Patients with FLT3-Mutated AML
2858 - Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
4579 - Influence of Oral Microbiota on Chronic Graft-Versus-Host Disease and Its Role As a Therapeutic Target

Enomoto, Y.

3952 - Mitotic Perturbation Is a Key Mechanism of Action of Decitabine in Myeloid Tumor Treatment

Enrico, A.

966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Enriquez, D. J.

445 - Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis

Ensbey, K. S.

861 - Regulatory T Cell Depletion during Stem Cell Mobilization Enhances Anti-Myeloma Immunity after Experimental Autologous Stem Cell Transplantation
3258 - Lithium Attenuates Graft-Versus-Host Disease Via Effects on the Intestinal Stem Cell Niche

Ensell, L.

3318 - Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

Enshaei, A.

1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
2834 - Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance

Enssle, J. C.

755 - Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
1500 - Proteomic Characterization of Acute Myeloid Leukemia

Enstrom, A.

3763 - A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Enstrom, M.

2527 - HSCs Engraft in a Stochastic Pattern and Form Clonal Pools after Transplantation

Enting, R.

4282 - Detection of Cell Free Tumor DNA in Plasma of Patients with Large B-Cell Lymphoma of the Sanctuary Sites By Digital Droplet PCR

Entrena Ureña, L.

1156 - Pilot, Multicenter and Cross-Sectional Study of Joint Health in Patients with Non-Severe Hemophilia

Entrop, J. P. P.

448 - Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway
4236 - Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Enver, T.

37 - Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Enzenmüller, S.

2828 - Venetoclax Resistance in B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Increased Mitochondrial Metabolism and Can be Overcome By Co-Targeting Oxidative Phosphorylation

Eoli, M.

1999 - Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Eom, H. S.

2912 - Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma
4274 - Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Eom, H. S.

2260 - Real-World Treatment Patterns and Outcomes of Patients with Newly Diagnosed Multiple Myeloma: An Analysis Using National Health Insurance Service Database

Eom, K. S.

425 - the Prognostic Value of Physical Function in Older Adults with Acute Myeloid Leukemia Treated with Low Intensity Treatment
1386 - Prognostic Value of Genomic Clusters Using Machine Learning in Older Adults with AML
1392 - Venetoclax with Decitabine Versus Decitabine Monotherapy in Elderly Acute Myeloid Leukemia: A Propensity Score Matched Analysis
2108 - Impact of Different Donor Types on Post-Transplant Disease Control in Patients with MDS Receiving Anti-Thymocyte Globulin (ATG)-Containing Conditioning
4696 - Reduced Toxicity FluBu3 Regimen Showed a Comparable Post-Transplant Outcomes to a Myeloablative BuCy Conditioing in Acute Myeloid Leukemia Patients Receiving First Allogeneic Hematopoietic Stem Cell Transplantation in MRD Negative CR1

Epari, S.

2976 - Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Epaud, R.

675 - Impact on Silent Infarct Incidence of Early Screening of the Extracranial Portion of the Internal Carotid in a Longitudinal Cohort-Study of Children with Sickle Cell Anemia

Epeldegui, M.

1595 - Elevated CCL22 and sIL2Rα Levels Precede the Diagnosis of Young Adult Classical Hodgkin Lymphoma: A Nested Case-Control Study from the DoD Serum Repository
1611 - Comparison of Chronic Health Conditions and Health Behaviors in Long-Term Young Adult Hodgkin Lymphoma (YAHL) Survivors to That of Their Unaffected Co-Twin Controls

Eplin, D. D.

987 - Efficacy and Safety of a Novel Non-Myeloablative Conditioning Regimen for Hematopoietic Cell Transplantation in Adults with Severe Aplastic Anemia

Epling-Burnette, P. K.

1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
4182 - Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-Cell Non-Hodgkin's Lymphoma (NHL)
4307 - SHP2 Inhibition Suppresses RAS-ERK Signaling, the Development of JAK2 Inhibitor Persistence, and MPN Development in Pre-Clinical Models of Myeloproliferative Neoplasms

Epperla, N.

154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
170 - Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1582 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
3611 - Cumulative Incidence and Outcomes of Transformed Follicular Lymphoma in the United States, 2000-2018
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues
4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Eppert, K.

2590 - The Role of Histone H3-K27M Mutation in Preleukemic HSC Expansion

Epstein, R. S.

1760 - Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents in a Real-World Setting

Epstein-Peterson, Z. D.

1592 - Identifying Primary Refractory Disease and Early Relapses in Peripheral T-Cell Lymphoma Using Baseline Characteristics, Minimal Residual Disease, and Mutational Profiling
1593 - Outcomes for Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma in the 21^st Century By Relapse Status, Salvage Therapy, and Receipt of Allogeneic Transplant
1608 - Emapalumab for Malignancy-Associated Hemophagocytic Lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center Experience
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Equitz, E.

3518 - Etiologies of Normocytic Anemia in Children

Er, J.

161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
1912 - Infectious Complications of Bispecific Antibody Therapy in Patients with Multiple Myeloma
4554 - Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Er, J. A.

1004 - The Birth of the Red Blood Cell: Dynamics of Erythroid Enucleation in the Bone Marrow Niche

Eradat, H.

348 - Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
3114 - Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Eran, A.

111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial

Erasmus, M. F.

4147 - A Novel Antibody-Drug Conjugate Directed Towards the Surrogate Light Chain of Malignantly-Transformed B-Cell Precursors Reverses Leukemic Progression in NSG Mice

Erazo, N.

4759 - Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with Calr-Mutated Myelofibrosis

Erba, H. P.

62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
225 - Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated with Improved Overall Survival
306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
1460 - Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
4023 - Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT^® Myeloid Registry Study
4027 - How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform
4076 - Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine and Venetoclax in Patients with Acute Myeloid Leukemia (ASPEN-05): Results from Phase 1a Dose Escalation Part
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative
4412 - Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Erbella, F.

553 - Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
2972 - Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study

Erbilgin, Y.

1684 - The Anti-HIV Drug Nelfinavir Exhibits Synergistic Activity with Tyrosine Kinase Inhibitors and Circumvents TKI-Resistance Conferred By T315I-Mutated BCR-ABL

Erdem, R.

4034 - Retrospective Analysis of Turkish AML Registry Database, on Behalf of AML Working Group of Turkish Society of Hematology

Erdmann-Gilmore, P.

533 - The Protein Interactomes of CBFB-MYH11 and RUNX1-RUNX1T1 Suggest Different Mechanisms of Action for Initiating Acute Myeloid Leukemia
3927 - The Protein Interactome of DNMT3A, and Altered Interactions Caused By Missense Mutations Associated with AML and/or the DNMT3A Overgrowth Syndrome

Erdos, K.

1723 - Unbiased Identification of Thrombosis Risk Factors in Polycythemia Vera (PV) Using Machine Learning and Rich Data from Automated Extraction of Medical Records Generates Dynamic Models Highly Predictive for Thrombosis in PV
3003 - JAK2^V617F Impairs T Cell Differentiation in Polycythemia Vera
3034 - Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2^V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Erez, O.

1181 - Levels and Activity of Von Willebrand Factor in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Erhardt, J.

1992 - FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma

Erickson, C.

480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39

Erickson, C.

456 - RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients
934 - Systematic Evaluation of AML-Associated Antigens Identifies Novel Anti-U5 snRNP200 Therapeutic Antibodies for the Treatment of AML

Erickson, C.

4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Erickson, S. B.

1176 - MAC Plus Study: A Retrospective Study Correlating DNA Variants, Clinical Course and Outcomes from 187 Patients Who Underwent Testing Using an Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathy Genetic Sequencing Panel

Erickson, S. W.

4050 - Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Erickson-Viitanen, S.

236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Erikson, C. E.

668 - Advanced Practice Providers (APPs) in Hematology: Work Practices, Interactions with Physicians, and Opportunities for Collaboration within the American Society of Hematology (ASH)

Eriksson, H.

1753 - Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271⁺ Mesenchymal Stromal Cells

Erisnor, G.

172 - "...Paying to be a Patient in the Hospital and the Parking Lot": Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers

Erkeland, S. J.

1960 - Novel Anti-CD117 Antibodies for Rapid and Efficient Hematopoietic Stem Cell Depletion and Safe Bone Marrow Conditioning

Erkers, T.

2797 - Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing
2802 - Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Erkner, E.

1286 - The Rorɣ/SREBP2 Pathway Is a Master Regulator of Cholesterol Metabolism and Serves As Potential Therapeutic Target in T(4;11) Leukemia
2599 - Different MLL Breakpoints Influence Leukemia Characteristics of MLL-Rearranged Cells in a Human CRISPR/Cas9-Based Model
2611 - Induction of t(9;22) (q34;q11) in Bone Marrow-Derived HSPCs Via CRISPR/Cas9 to Reveal the Differences of the Leukemogenic Properties of p210^BCR/ABL1 and p185^BCR/ABL1

Erlacher, M.

494 - Germline SAMD9/9L MDS Predisposition Syndromes Are Characterized By Complex Clonal Architecture and Lineage-Specific Escape Mechanisms Including Somatic Genetic Rescue in T and B Lymphocytes
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
2577 - Online Platform for SAMD9 and SAMD9L Variant Annotation and Phenotype Correlation
3902 - Transient Monosomy 7 Is a Rare Event in Young Children with SAMD9L Syndrome
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
- Myelodysplastic Syndrome and Leukemia Is a Secondary Event after Bone Marrow Failure in Gata2 Haploinsufficient Mice
- Q&A

Erlanson, M.

614 - Long-Term Follow-up of Clinical Outcome Determinants and Correlative Biological Features from the Nordic NLG-T-01 Trial

Erler-Yates, N.

3204 - Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Ermann, D. A.

447 - Survival Disparities Among People with HIV and Diffuse Large B-Cell Lymphoma in the Era of Novel Antiretroviral Therapy
450 - T-Cell Prolymphocytic Leukemia: Trends in Overall Survival Demonstrate Marginal Improvement over Time and Minimal Benefit with Currently Available Treatments
2967 - Treatment and Overall Survival Outcomes of Patients with B-Cell Prolymphocytic Leukemia
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Ernst, F. R.

1178 - Use of Plasmic Scores to Aid Diagnosis of aHUS: A Real-World Analysis of Hospitalized Patients from the Premier Healthcare Database

Ernst, P.

336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Ernst, T.

332 - ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase
622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
3057 - Clinicohematologic and Molecular Response of Essential Thrombocythemia Patients Treated with Pegylated Interferon-Alpha: A Multicenter Study on Behalf of the German Study Group-MPN (GSG-MPN)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Ero, M.

1176 - MAC Plus Study: A Retrospective Study Correlating DNA Variants, Clinical Course and Outcomes from 187 Patients Who Underwent Testing Using an Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathy Genetic Sequencing Panel

Erpelinck-Verschueren, C.

37 - Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Erra, A.

2696 - A Nationwide Analysis of Clinical Outcomes and Baseline Characteristics in Patients Admitted with ALL and Prior Malignancy
2700 - Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML

Ertay, A.

2877 - DC-SIGN Binding to the Oligomannose-Type Glycans on the Surface Immunoglobulin Variable Region of Follicular Lymphoma Promotes Selective Adhesion to Microenvironmental VCAM-1

Escaig, R.

1084 - Immunothrombotic Signatures of Resident and Circulating Immune Cells in Human Infective Endocarditis Revealed By Multi-Omic Profiling

Escalante Barrigón, F.

104 - Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy
1524 - Clonal Architecture and Evolution of Waldenström’s Macroglobulinemia at the Single Cell Level

Escalante, F.

118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
1881 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
4549 - Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Escalon, J.

1874 - Extramedullary Relapse Post CAR-T
3315 - Immune Recovery Post BCMA CAR-T: Implications for Infection Prophylaxis and Vaccinations

Escamilla Gomez, V.

363 - Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease
3451 - Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Escano, L.

2769 - Targeting the WT1^mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia

Escayola, D. A.

530 - U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies

Escherich, C.

411 - Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children
- Targeted Sequencing in Pediatric ALL Identifies Lineage-Specific Enrichment of TCF3 Germline Variants
- Q&A

Escherich, G.

1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Escobar, A.

4219 - Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma

Escobar, B. P.

357 - Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target

Escobar, M.

1188 - The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
3792 - Bleeding Phenotype Does Not Appear to Correlate with Factor VIII Levels or Genetic Mutation in an Exclusive Pediatric Cohort of Hemophilia a Carriers
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas
4780 - BAX 335 Hemophilia B Gene Therapy Phase 1/2 Clinical Trial: Long-Term Safety and Efficacy Follow-up
4839 - Cardiovascular Disease Prevention in Persons with Hemophilia

Escoda, L.

4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
4275 - Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Escoffre-Barbe, M.

50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
3212 - Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Escolar, G.

3307 - Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Escribà-García, L.

164 - Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30⁺ T-Cell Lymphoma: Clinical and Biological Studies

Escribano Serrat, S.

3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Escudero-López, E.

164 - Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30⁺ T-Cell Lymphoma: Clinical and Biological Studies

Escuerdo, A.

4007 - Familial Predisposition to B-Cell Precursor Acute Lymphoblastic Leukemia Mediated By PAX5 Germline Variants

Eskelund, C. W.

4170 - Exploring New Prognostic Biomarkers in Mantle Cell Lymphoma: The Best RNA Based Risk Score

Eskridge, P.

2192 - Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team

Eslin, D.

3739 - Investigating Biomarkers for Primary Immunodeficiency Disorders in Patients with Autoimmune Cytopenia

Espada, E. L.

363 - Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Espadas, C. J.

3549 - Financial Impact of Imatinib Discontinuation in Brazil – a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution

Espagnolle, N.

2558 - A Functional in Vitro 3D Model of Human Hematopoietic Niches

Español, I.

269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Español-Rego, M.

3278 - Identification of Molecular Mechanisms Governing CAR-T Cell Response in MM Patients Using Single Cell Transcriptomics
4648 - CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

Esparza, O.

4315 - Dysregulated Autophagy in Platelets from JAK2^V617F-Positive Polycythemia Vera and Essential Thrombocythemia Underlies Bioenergetic Failure As a Possible Mechanism for Thrombohemorrhagic Complications

Esperalba, J.

1103 - Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic

Espigado, I.

3077 - SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients with Lower-Risk Myelodysplastic Syndrome

Espin Palazon, R.

821 - A Link between Blood Flow and the Inflammatory Networks That Govern Hematopoietic Stem Cell Specification
- Deconstructing Inflammatory Dynamics during Hematopoietic Stem Cell Development
- Q&A

Espinet, B.

1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
4429 - Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL

Espinet, B.

2177 - Pilot Inter-Laboratory Comparison Study of Optical Genome Mapping Analysis for Cytogenomic Characterization of Hematological Malignancies: A Spanish Multicentric Study

Espinola, R.

4673 - Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
4910 - Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Espinosa, J. M.

2524 - Mirages – REDS Explorer: An Online Portal for Longitudinal Metabolomics Data from the REDS-III RBC Omics Study

Espinoza, A. I.

3194 - A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy

Espinoza Gutarra, M.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma

Espinoza, M.

4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Espinoza, M.

3199 - Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup
4042 - Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Espinoza-Gutarra, M. R.

1080 - Racial Breakdown of Sickle Cell Disease Complications and Hospitalization Outcomes: Nationwide Inpatient Sample
3826 - Emerging Thrombotic Complications in Patients Undergoing Chimeric Antigen Receptor T Cell Therapies

Esplin, E. D.

3186 - Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma

Esplin, I.

1812 - Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Esposito, E.

260 - A 7-Gene Signature in Unmanipulated Leukaphereses Correlates with in-Vivo CAR T-Cell Expansion and Survival of Lymphoma Patients Receiving Tisagenlecleucel or Axicabtagene Ciloleucel Therapy

Esposito, F.

4195 - A Digital Gene-Expression Signature Supports Mediastinal Gray Zone Lymphoma Stratification within Classical Hodgkin or Primary Mediastinal B-Cell Lymphoma

Esposito, M.

3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Esposito, O.

4346 - BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Esposito, S.

785 - Adaptive Routes of Hematopoietic Stem Cell Differentiation to Disease Conditions and Age in Gene Therapy Patients

Esposito Vangone, B.

2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine

Esqueda, D.

168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Esquirol, A.

164 - Phase 1 Clinical Trial of Memory-Enriched Academic HSP-CAR30 for the Treatment of Relapsed/Refractory Hodgkin Lymphoma and CD30⁺ T-Cell Lymphoma: Clinical and Biological Studies
3397 - Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Esrick, E. B.

2525 - Altered Cellular Sedimentation during Apheresis Impacts Outcomes of Peripheral Blood Stem Cell Collection Efficiency in Patients with Sickle Cell Disease
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Essa, M.

2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party

Eßeling, E.

390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
3377 - Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Essell, J.

4257 - A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)
4673 - Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Esselmann, J.

3588 - Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy

Essenmacher, A.

2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Essers, M.

2554 - Unraveling and Visualizing the Interactions of Acute Myeloid Leukemia with the Bone Marrow Microenvironment in Vitro and In Vivo

Estabrook, J.

3859 - Chronic IL1β Exposure Enhances Self-Renewal Ability and Myeloid Priming in TET2 Deficient Stem and Progenitor Cells

Esteb, C.

2604 - CCRL2 Promotes Cytokine-Regulated Growth of Erythroleukemia Cells

Estébanez, B.

4704 - Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism

Esteghamat, N. S.

2764 - A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
3205 - Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
3538 - Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records
4024 - Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens
4520 - Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California

Estell, J.

4568 - Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Estella, J. J.

2789 - DNA and RNA Profiles in Machine Learning Algorithm to Predict Which Patients with AML/MDS Will Respond to Venetoclax-Based Therapy
3488 - Liquid Immunophenotyping and the Diagnosis of Lymphoid Neoplasms Using Cell-Free RNA

Esteller, M.

721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features

Estepa, M. D.

40 - CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Estepp, J. H.

181 - Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)
1030 - Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent Thalassemia

Esteve, J.

2136 - Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party
3284 - CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia

Esteve, J.

2063 - Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT
2082 - Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT
2095 - Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT
3391 - Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Estey, E. H.

597 - Prognostic Impact of Secondary Versus De Novo Ontogeny in Acute Myeloid Leukemia (AML) Is Predominantly Accounted for By the European Leukemianet (ELN) 2022 Risk Classification
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Estoppey, C.

353 - ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens
2775 - Preclinical Evaluation of ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of AML and T-ALL

Estrabaut, M.

2210 - Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O)

Estrada, N.

1701 - Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line

Estrada-Merly, N.

374 - Comparison of Allogeneic Hematopoietic Cell Transplantation Outcomes from Younger Matched Unrelated Donor Versus Older Sibling Donor for Acute Myeloid Leukemia
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
4729 - Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
4871 - Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Estrella, B.

147 - First-in-Class Histone Acetyltransferase (HAT) Activator, YF2, Modulates Immune Evasion in DLBCL, Enhancing the Effects of Immune Checkpoint Blockade

Estrov, Z. E.

95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
1756 - RAS Pathway Mutations Are Associated with Progression after Hypomethylating Agent Therapy in Chronic Myelomonocytic Leukemia
4353 - Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years
4435 - Early Treatment with Ofatumumab in Patients with High-Risk CLL

Estwick, T.

2408 - Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease

Etancelin, P.

4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Etchin, J.

4587 - Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment

Etekal, T.

2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis

Ethell, M. E.

4217 - Autologous Transplantation in First Remission in the Rituximab Era in Patients with Mantle Cell Lymphoma: Experience from the Royal Marsden Hospital

Ethier, V.

2887 - Prognostic Significance of Interim PET/CT in Follicular Lymphoma Treated with Frontline Chemoimmunotherapy

Ethiraj, P.

705 - Perturbation of Intermediary Metabolism Inhibits Glycolysis, Oxidative Phosphorylation, Amino Acid Synthesis and Prevents Lymphoma Development in Mice
846 - Alpha-Ketoglutarate Suppresses MYC and mTORC1 and Displays Anti-Lymphoma Activity

Etienne, G.

622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
1705 - Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.
1726 - Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Etienne, G.

3016 - Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML
4343 - Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Etienne-Julan, M.

183 - Hydroxyurea Is Associated with Later Onset of Occurrence of Acute Splenic Sequestration Episodes in Sickle Cell Disease: Lessons from the European Sickle Cell Disease Cohort – Hydroxyurea (ESCORT-HU) Study
1069 - Long-Term Efficacy and Safety of L-Glutamine in Preventing Sickle Cell Disease-Related Acute Complications and Hemolysis in Pediatric and Adult Patients: A Real-World Observational Study

Eto, T.

368 - Indirectly Recognizable Epitopes Derived from Recipient Mismatched HLA-B Are Associated with Adverse Prognosis in Single-Unit Cord Blood Transplantation
990 - Reduced-Intensity Conditioning with Fludarabine/Busulfan Versus Fludarabine/Low-Dose Melphalan in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4755 - Donor Selection Considering Donor Age in Hematopoietic Cell Transplant Recipients 50-75 Years of Age

Etra, A.

770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Ettala, P.

835 - Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Etuk, A.

2001 - Tvt CAR7: Phase 1 Clinical Trial of Base-Edited “Universal” CAR7 T Cells for Paediatric Relapsed/Refractory T-ALL
3306 - Single and Combinational Multiplex Base-Edited ‘Universal’ CAR T Cells in a Humanised Model of Primary CD7+CD33+ AML

Eva, D. D.

3978 - Orthotopic Xenografts Models in Relapse/Refractory Lymphomas: A Preclinical Model for Therapeutic, Mechanistic and Functional Studies
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)
4240 - Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Evandy, C.

483 - Interleukin 18 Suppresses Regeneration of the Thymus
4581 - The Zinc-Sensing Receptor GPR39 Is a Master Regulator of Immune Reconstitution after Bone Marrow Transplant in the Thymus and in the Bone Marrow

Evangelista, A.

4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Evangelista, A.

733 - PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Evans, A. G.

1558 - Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Evans, A. G.

1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
3492 - Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Evans, E.

2217 - Financial Coping Strategies and Financial Assistance Following a Pediatric Hematologic Malignancy

Evans, E. N.

2366 - GBT021601 Increases Hemoglobin and Improves Red Blood Cell Deformability without Rebound Hyperviscosity upon Drug Clearance in a Sickle Mouse Model

Evans, F.

412 - Biallelic Deleterious Germline SH2B3 Variants Cause a Novel Clinical Syndrome of Myeloproliferation and Multi-Organ Autoimmunity

Evans, G.

1128 - Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Evans, J.

1887 - Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database

Evans, K.

4050 - Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Evans, K.

4820 - Clinical and Economic Outcomes in Patients with Transfusion-Dependent β-Thalassemia and Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises Receiving Hematopoietic Stem Cell Transplants in the United States

Evans, L.

1287 - Identifying Mechanisms of Resistance to DHODH Inhibition in Cancer

Evans, M. S.

4779 - The Effects of Immunomodulation with Corticosteroids to Manage an AAV Capsid Immune response in the Phase I/II Study of SPK-8011

Evans, N.

4327 - A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Evans, P.

266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
2132 - T-Cell Replete Unrelated Cord Blood Transplant Give Superior Outcomes to Other Donor Sources in High Risk and Relapsed/Refractory Paediatric Myeloid Malignancy

Evans, W. E.

719 - Pharmacotypes across the Genomic Landscape of Pediatric Acute Lymphoblastic Leukemia and Impact on Treatment Response
1301 - Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment
2625 - Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia

Evavold, B.

2425 - Actin Bundling Protein L-Plastin Regulates Megakaryocyte Membrane Rigidity and Platelet Spreading

Eveillard, J. R.

1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Eveillard, M.

873 - Early In Vivo Generation of Vγ9Vδ2 T Cells after Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide: A Monocentric Phase 1 Study
3420 - Higher Proportions of Monocytic-Myeloid-Derived Suppressive Cells (mMDSC) before Allotransplant Predict Relapse in Acute Leukemia Patients
4404 - Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Evens, A. M.

154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2835 - Identification of Genetic Subtypes in Follicular Lymphoma
2885 - FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Evens, A. M.

313 - Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Evensen, N. A.

2818 - The Role of Relapse Specific over-Expression of S100A8/A9 B Leukemic Cells in Promoting Chemoresistance

Everett, J.

3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector

Everette, K.

679 - Base Editing of Hematopoietic Stem Cells Rescues T-Cell Development for CD3d Severe Combined Immunodeficiency

Evers, A. W.

1369 - Hydrocortisone or Placebo to Reduce Dexamethasone-Induced Neurobehavioral Side Effects: Results of a Phase 3 National, Double-Blind, Placebo-Controlled Randomized Trial with Crossover Design

Evers, L. M.

1800 - Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Eves, P. T.

1933 - A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis

Evliati, L.

3667 - Real-World Data on the Use of Luspatercept in Greek Patients with Transfusion Dependent Thalassemia

Ewalt, M. D.

4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Ewara, E.

3581 - External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Ewenstein, B.

1152 - Risk of Intracranial Hemorrhage in US Patients with Hemophilia a: Real-World Retrospective Cohort Study Using the Athndataset

Ewesuedo, R.

2776 - Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Ewing, J.

739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Ewing, J.

4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Ewington, L. J.

LBA-5 - Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial

Exbrayat, C.

2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Exner, A.

4620 - Non-Invasive Tracking of Nanobubble Tagged Natural Killer Cells Using Clinical Ultrasound

Exter, B.

626 - Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)

Eyassu, F.

2637 - Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Eyquem, J.

3155 - Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
3296 - Highly Parallel Discovery of Synthetic Knockin Sequences for Enhanced Cancer Immunotherapies

Eyre, T. A.

1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)
1815 - Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Eyre, T. A.

153 - Impact of Double Expression of MYC and BCL-2 on Outcomes in Primary CNS Lymphoma: A UK Multicentre Analysis
229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
1544 - Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide
1574 - Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4627 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Eyster, M. E.

783 - Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011
4783 - Rapid Clearance of Vector Following AAV-Mediated FVIII Gene Transfer in the Phase I/II Trial of SPK-8011 in People with Hemophilia A

Eythorsson, E.

103 - Prevalence of MGUS Is High in the Istopmm Study but the Prevalence of IgA MGUS Does Not Increase with Age in the Way Other Immunoglobulin Subtypes Do
105 - Sars-Cov-2 Vaccinations Do Not Lead to Progression of Monoclonal Gammopathy of Undetermined Significance: Results from the Population-Based Istopmm Screening Study
107 - Predicting the Need for Upfront Bone Marrow Sampling in Individuals with MGUS: Derivation of a Multivariable Prediction Model Using the Prospective Population-Based Istopmm Cohort
967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
4455 - Circulating Tumor Plasma Cells in the Screened Istopmm Smoldering Multiple Myeloma Cohort
4504 - Monoclonal Gammopathy of Undetermined Significance (MGUS) with Multiple Paraproteins: Results from the Population-Based Istopmm Screening Study
4507 - Autoimmune Diseases Are Not Associated with Monoclonal Gammopathy of Undetermined Significance: Results of the Prospective Population-Based Istopmm Study
4537 - Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study
4541 - Monoclonal Gammopathy of Undetermined Significance and Risk of Chronic Kidney Disease: Results of the Population-Based Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Ezekwesili, C.

3572 - Prevention and Management of Sickle Cell Pain Crises: Lessons Learned from Older Adults with Sickle Cell Disease

Ezekwudo, D. E.

1186 - Assessing the Rate of Compliance with the Revised Sapporo/Sydney Criteria in Diagnosing Antiphospholipid Syndrome: A Multicenter Retrospective Analysis

Ezponda, T.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
1751 - Bone Marrow Microenvironment Changes in Myelodysplastic Neoplasms and Its Relationship with Clonal Hematopoiesis and Disease Progression
2597 - Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes

Ezzaldin, N.

2991 - Efficacy of Levofloxacin Versus Amoxicillin/Clavulanate and Ciprofloxacin in the Outpatient Management of Low-Risk Febrile Neutropenia in Children with Cancer; A Randomised Control Study

Ezzat, H. M.

2249 - Evidence Gaps in the Management of Patients with Sickle Cell Disease (SCD) by Non-specialist Healthcare Professionals (HCPs): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)
4887 - Sickle Cell Disease (SCD) Burden on Patients Treated With Hydroxyurea (HU): Results from the Real-World Assessment Survey for SCD in Saudi (ROARS)

Author Index: E